Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KarXT + KarX-EC for cognitive impairment in Alzheimer's disease
NL-OMON61590Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of xanomeline and trospium in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoints: Change from baseline in ADAS-Cog11 at Week 24 and CIBIC+ at Week 24. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
xanomelinetrospium
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON61590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61590.